The Valley Desk

Case reportCureusPublished

Severe Dermatologic Toxicity During Amivantamab-Lazertinib Treatment in Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer

Read the publication ↗ Open access copy ↗

Regional connection

Verified Author affiliations on the Europe PMC record name Cooper Norcross Health, Cooper Medical School of Rowan University, with Rowan University linked by the institution reference. Affiliation source

Publication record

Type
Case report
Venue
Cureus
Published
Subject terms
Non-small cell lung cancer (NSCLC); Epidermal Growth Factor Receptor (Egfr); Cutaneous Adverse Drug Reaction; Lazertinib; Amivantamab
PubMed ID
42824853
PubMed Central ID
PMC13629737
Open access
Yes, open
Added to directory
Source checked

Report a correction or request removal